• 1
    Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves. Int J Radiat Oncol Biol Phys. 1985; 11: 16991707.
  • 2
    Deacon J, Peckham MJ, Steel GG. The radioresponsiveness of human tumours and the initial slope of the cell survival curve. Radiother Oncol. 1984; 2: 317323.
  • 3
    Malaise EP, Fertil B, Chavaudra N, Guichard M. Distribution of radiation sensitivities for human tumor cells of specific histological types: Comparison of in vitro to in vivo data. Int J Radiat Oncol Biol Phys. 1986; 12: 617624.
  • 4
    White CA, Halpern SE, Parker BA, et al. Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti-idiotype monoclonal antibodies. Blood. 1996; 87: 36403649.
  • 5
    Press OW, Eary JF, Badger CC, et al. Radiolabeled antibody therapy of human B cell lymphomas. Adv Exp Med Biol. 1991; 303: 9196.
  • 6
    O'Donoghue J. Dosimetric principles of targeted radiotherapy. In: AbramsPa F, AR, ed. Radioimmunotherapy of Cancer. New York: Marcel Dekker; 2000: 120.
  • 7
    Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 37933803.
  • 8
    Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti- CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clinical Cancer Res. 1996; 2: 457470.
  • 9
    Witzig TE, Gordon LI, Cabanillas F, et al. Randomized Controlled Trial of 90Y-Labeled Ibritumomab Tiuxetan (Zevalin') Radioimmunotherapy versus Rituximab Immunotherapy for Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-cell Non-Hodgkin's Lymphoma. J Clin Oncol. 2002; 20: 24532463.
  • 10
    Gordon LI, Witzig T, Molina A, et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin Lymphoma. 2004; 5: 98101.
  • 11
    Ansell SM, Ristow KM, Habermann TM, Wiseman GA, Witzig TE. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan for Non-Hodgkin's lymphoma. J Clin Oncol. 2002; 20: 38853890.
  • 12
    Cheson B, Horning S, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol. 1999; 17: 12441253.
  • 13
    Courtenay VD. The response to continuous irradiation of the mouse lymphoma L 5178Y grown in vitro. Int J Radiat Biol Relat Stud Phys Chem Med. 1965; 9: 581592.
  • 14
    Yau TM, Gregg EC, Kim SC. Production of radioresistant mutants in murine L5178Y lymphoma cells. Radiat Res. 1979; 80: 502511.
  • 15
    Beer JZ, Mencl J, Horng MF, Gregg EC, Evans HH. Effects of low dose rate (0.003–0.025 Gy/h) chronic X-irradiation on radioresistant and radiosensitive L5178Y mouse lymphoma cells. Int J Radiat Biol Relat Stud Phys Chem Med. 1985; 48: 609619.
  • 16
    Kaminski MS, Tuck M, Estes J, et al. 131I-Tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005; 352: 441449.
  • 17
    Horning SJ, Younes A, Jain V, et al. Efficacy and safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005; 23: 712719.
  • 18
    Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: A multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984; 10: 489497.
  • 19
    Kamath SS, Marcus RBJr, Lynch JW, Mendenhall NP. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 1999; 44: 563568.
  • 20
    Tsang RW, Gospodarowicz MK, Pintilie M, et al. Stage I and II MALT lymphoma: Results of treatment with radiotherapy. Int J Radiat Oncol Biol Phys. 2001; 50: 12581264.
  • 21
    Johannsson J, Specht L, Mejer J, Jensen BA. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's lymphoma and chronic lymphocy tic leukemia. Int J Radiat Oncol Biol Phys. 2002; 54: 14661470.
  • 22
    Sawyer EJ, Timothy AR. Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma. Radiother Oncol. 1997; 42: 4951.
  • 23
    Macklis R, White C. Rationale and feasibility of combined radiotherapy and anti-CD20 immunotherapy in CD20+ B-cell NHL. Am Soc Ther Radiol Oncol (ASTRO). 2002; 54( Suppl): 141142.
  • 24
    Vogel CA, Galmiche MC, Buchegger F. Radioimmunotherapy and fractionated radiotherapy of human colon cancer liver metastases in nude mice. Cancer Res. 1997; 57: 447453.
  • 25
    Sun LQ, Vogel CA, Mirimanoff RO, et al. Timing effects of combined radioimmunotherapy and radiotherapy on a human solid tumor in nude mice. Cancer Res. 1997; 57: 13121319.
  • 26
    Ruan S, O'Donoghue JA, Larson SM, et al. Optimizing the sequence of combination therapy with radiolabeled antibodies and fractionated external beam. J Nucl Med. 2000; 41: 19051912.